Skip to main content
FDA approves use of Lynparza for advanced pancreatic cancer

The FDA has approved AstraZeneca and Merck's Lynparza as a first-line maintenance therapy for patients who have BRCA mutations and advanced pancreatic cancer that has spread beyond the pancreas but not worsened after 16 weeks of chemotherapy. The drug was previously approved as treatment for breast and ovarian cancers.

Full Story: